AIM · AIM ImmunoTech Inc.
$0.26
+0.01 (+2.09%)
At close · Aug 21
Going-concern doubt
— flagged Aug 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company has incurred losses from operations and operating cash outflows exceeded cash inflows from operating activities for the six months ended June 30, 2026. These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements.”View the 10-Q filed Aug 7, 2026
Market Cap
$7.87M
Shares
30.44M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$88K
-48.2%
FY2025
Net Income
-$13.96M
+19.4%
FY2025
Gross Margin
-535.03%
+187.6pp
FY2014
Operating Margin
-13254.55%
-1624pp
FY2025
Diluted EPS
-$8.62
+72.1%
FY2025
Operating Cash Flow
-$10.96M
+26.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $95K | $88K | $170K | $202K | $141K | $135K | $163K | $140K | $367K | $437K | $92K | $133K | $197K | $150K | $213K | $161K | $135K | $111K | |
| $1.56M | — | — | — | — | — | — | — | — | — | — | — | $1.25M | $1.23M | $1.99M | $1.04M | $1.34M | $584K | |
| -$1.41M | — | — | — | — | — | — | — | — | — | — | — | -$1.05M | -$1.08M | -$1.78M | -$882K | -$1.21M | -$473K | |
| — | — | — | — | — | — | — | — | — | — | — | — | -535.03% | -722.67% | -833.8% | -547.83% | -893.33% | -426.13% | |
| $2.74M | $3.92M | $6.2M | $10.94M | $6.99M | $7.67M | $5.72M | $4.65M | $4.78M | $4.1M | $5.11M | $8.04M | $8.99M | $8.36M | $9.51M | $6.72M | $7.61M | $7M | |
| $8.38M | $7.7M | $13.71M | $21.14M | $13.07M | $8.67M | $8.65M | $7.04M | $6.2M | $6.57M | $7.68M | $7.15M | $9.06M | $7.72M | $9.06M | $6.69M | $7.57M | $5.8M | |
| — | $173K | $209K | $199K | $218K | $116K | $68K | $57K | $22K | $56K | $50K | $34K | $31K | $196K | — | — | — | — | |
| $11.23M | $11.75M | $19.94M | $32.12M | $20.06M | $18.97M | $15.32M | $12.58M | $11.86M | $11.85M | $13.9M | $16.78M | $19.3M | $17.32M | $20.55M | $14.46M | $16.52M | $13.38M | |
| -$11.14M | -$11.66M | -$19.77M | -$31.92M | -$19.92M | -$18.84M | -$15.15M | -$12.44M | -$11.5M | -$11.42M | -$13.8M | -$16.65M | -$19.1M | -$17.17M | -$20.34M | -$14.3M | -$16.39M | -$13.26M | |
| — | -13254.55% | -11630.59% | -15800% | -14129.79% | -13954.07% | -9295.71% | -8887.86% | -3132.43% | -2612.36% | -15004.35% | -12518.8% | -9694.92% | -11444.67% | -9549.3% | -8878.88% | -12138.52% | -11949.55% | |
| $1.14M | $812K | $585K | — | — | $67K | $672K | $427K | $201K | — | — | $3000 | $11K | $16K | $24K | $41K | $11K | $0 | |
| — | $3.18M | $5.19M | $1.07M | $629K | — | — | — | — | — | — | — | — | $775K | $1.57M | $583K | $2.37M | — | |
| -$3000 | $17K | -$93K | $200K | -$1.68M | -$201K | $219K | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$13.96M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$14.27M | -$13.96M | -$17.32M | -$28.96M | -$19.45M | -$19.13M | -$14.4M | -$9.4M | -$9.83M | -$8.26M | -$7.5M | -$15.23M | -$17.45M | -$16.23M | -$17.35M | -$9.02M | -$13.14M | -$7.18M | |
| — | -15861.36% | -10188.24% | -14337.62% | -13790.78% | -14168.15% | -8834.36% | -6717.14% | -2677.66% | -1889.93% | -8154.35% | -11451.13% | -8857.87% | -10816.67% | -8147.42% | -5599.38% | -9730.37% | -6468.47% | |
| — | — | -$17.32M | -$28.96M | -$19.45M | -$19.08M | -$14.45M | -$9.4M | -$9.83M | -$8.24M | -$7.41M | -$15.17M | -$17.5M | -$16.3M | — | — | — | — | |
| USD/shares | — | -$8.62 | -$30.92 | -$58.20 | -$38.80 | -$38.80 | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$8.62 | -$30.92 | -$58.20 | -$38.80 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 1.62M | 560.17K | 500.92K | — | 488.08K | 328.3K | 37.56K | 10.35K | 295.65K | 224.95K | 202.89K | 161.77K | 1.73M | 1.45M | 1.4M | 1.38M | — |
| shares | — | 1.62M | 560.17K | 500.92K | 495.37K | 488.08K | 328.3K | 37.56K | 10.35K | 295.65K | 224.95K | 202.89K | 161.77K | 1.73M | 1.45M | 1.4M | 1.38M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
16.03×
Peer median 1.54×
EV/EBIT
—
Peer median 11.20×
P/E (TTM)
—
Peer median 3.14×
Peer medians compare against the 193 similar-size Biotechnology companies (of 545 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2022 | FY2021 | FY2020 |
|---|---|---|---|
| Clinical Treatment Programs US | $141,000 | $135,000 | $144,000 |
| Clinical Treatment Programs Europe | — | — | $19,000 |
Key facts
CIK
946644
CUSIP
00901B303
13F (30d)
17 filings
17 filers
Visit website
Investor relations